Wintermute Biomedical participated in BioTrinity 2024, connecting with European biotechnology, pharmaceutical and investment leaders and introducing the Solexan development programme to potential international partners.
Wintermute Biomedical participated in BioTrinity 2024 in London, joining biotechnology executives, investors, pharmaceutical companies and business development leaders from across the international life sciences sector.
BioTrinity is a leading European biopharma industry and investment conference, providing emerging biotechnology companies with opportunities to connect with potential investors, strategic partners and pharmaceutical organisations.
Wintermute’s participation at BioTrinity provided an important opportunity to introduce the Company and its lead development programme, Solexan™, to the European biotechnology and investment community.
Through a programme of partnering meetings and industry engagement, Wintermute connected with organisations interested in innovative therapeutic technologies and explored opportunities to support the continued development of Solexan™.
The conference provided valuable opportunities to build new relationships, understand international partnering priorities and increase awareness of Wintermute and its novel antiviral technology.
Participation at BioTrinity formed part of Wintermute Biomedical’s strategy to develop relationships with pharmaceutical companies, investors and potential strategic partners internationally.
These early connections contribute to the network of relationships supporting Wintermute as we work to advance Solexan™ through clinical development and towards a potential new treatment option for people affected by shingles.